

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Frederic Colland, et al.

Application No.: 10/520,712

Filed: December 22, 2005

For: Use of Specified TCF Target
Genes to Identify Drugs for the
Treatment of Cancer, In Particular
Colorectal Cancer, in which TCF/ β -
Catenin/Wnt Signalling Plays a
Central Role

Examiner: Laura B. Goddard

Art Unit: 1642

Conf. No.: 2640

CERTIFICATE OF ELECTRONIC TRANSMISSION
UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, including listed
enclosures, is being electronically transmitted in Portable
Document Form (PDF) through EFS-Web via Hyper Text
Transfer Protocol in accordance with 1.8(a)(4) to the United
States Patent and Trademark Office on:

Dated:

Signed:

6/24/08
Jere Valles
Jere Valles

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This amendment is in response to the Office Action mailed March 25, 2008. A
petition for a two-month extension of time and the required fee are being filed on or
before June 25, 2008, making this a timely response. Although Applicants do not believe
any additional fees are required, the Commissioner is hereby authorized to charge any
such fees, including extension fees and additional claim fees, or credit any overpayment,
to Deposit Account No. 50-0310 (Attorney Docket No. 067670-5005-US01).

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 10 of this paper.